MKI67 and melanoma: An earlier study showed that a low percentage of Ki67+EOMES+CD4+ T cells at baseline (but not under treatment) was associated with the occurrence of irAE in a study using adjuvant treatment of stage III and stage IV melanoma patients with anti-CTLA antibody ipilimumab [39].